Lishan Su

ORCID

Publication Activity (10 Years)

Years Active: 2016-2023
Publications (10 Years): 9

Top Venues

Science translational medicine

PLoS pathogens

The Journal of experimental medicine

Nature communications

University of North Carolina at Chapel Hill School of Medicine

Harvard University (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

University of North Carolina at Chapel Hill School of Medicine

United States

Professor :: Lineberger Cancer Center

Education History

Harvard University

United States

PHD

Publications

Mingyue Liu, Xu Wang, Xuexiang Du, Wei Wu, Yan Zhang, Peng Zhang, Chunxia Ai, Martin Devenport, Juanjuan Su, Musleh M Muthana, Lishan Su, Yang Liu, Peng Zhang
Soluble CTLA-4 mutants ameliorate immune-related adverse events but preserve efficacy of CTLA-4- and PD-1-targeted immunotherapy. Science translational medicine 15 (685) (2023)
Mingyue Liu, Xu Wang, Xuexiang Du, Wei Wu, Yan Zhang, Peng Zhang, Chunxia Ai, Martin Devenport, Juanjuan Su, Musleh M Muthana, Lishan Su, Yang Liu, Peng Zhang
Soluble CTLA-4 mutants ameliorate immune-related adverse events but preserve efficacy of CTLA-4- and PD-1-targeted immunotherapy. Science translational medicine 15 (685) (2023)
Mingyue Liu, Xu Wang, Xuexiang Du, Wei Wu, Yan Zhang, Peng Zhang, Chunxia Ai, Martin Devenport, Juanjuan Su, Musleh M Muthana, Lishan Su, Yang Liu, Peng Zhang
Soluble CTLA-4 mutants ameliorate immune-related adverse events but preserve efficacy of CTLA-4- and PD-1-targeted immunotherapy. Science translational medicine 15 (685) (2023)
Shishuo Sun, Chao Huang, Mengmeng Lu, Heng Xu, Yifan Yuan, Wanxin Zhao, Xiaolei Hu, Bixi Wang, Wei Zhang, Xiaoge Gao, Jun-Nian Zheng, Lishan Su, Qing Zhang
Herpes virus entry mediator costimulation signaling enhances CAR-T cell efficacy against solid tumors through metabolic reprogramming. Cancer immunology research (2023)
Véronique Godot, Colas Tcherakian, Laurine Gil, Iñaki Cervera-Marzal, Guangming Li, Liang Cheng, Nicolas Ortonne, Jean-Daniel Lelièvre, Giuseppe Pantaleo, Craig Fenwick, Mireille Centlivre, Hugo Mouquet, Sylvain Cardinaud, Sandra M Zurawski, Gerard Zurawski, Pierre Milpied, Lishan Su, Yves Lévy
TLR-9 agonist and CD40-targeting vaccination induces HIV-1 envelope-specific B cells with a diversified immunoglobulin repertoire in humanized mice. PLoS pathogens 16 (11) (2020)
Franck J Barrat, Lishan Su
A pathogenic role of plasmacytoid dendritic cells in autoimmunity and chronic viral infection. The Journal of experimental medicine 216 (9) (2019)
Wenwen Bi, Wei Xu, Liang Cheng, Jing Xue, Qian Wang, Fei Yu, Shuai Xia, Qi Wang, Guangming Li, Chuan Qin, Lu Lu, Lishan Su, Shibo Jiang
IgG Fc-binding motif-conjugated HIV-1 fusion inhibitor exhibits improved potency and in vivo half-life: Potential application in combination with broad neutralizing antibodies. PLoS pathogens 15 (12) (2019)
Chia-Lin Chen, Jeffrey Y Huang, Chun-Hsiang Wang, Stanley M Tahara, Lin Zhou, Yasuteru Kondo, Joel Schechter, Lishan Su, Michael M C Lai, Takaji Wakita, François-Loïc Cosset, Jae U Jung, Keigo Machida
Hepatitis C virus has a genetically determined lymphotropism through co-receptor B7.2. Nature communications 8 (2017)
Danming Zhu, Longchao Liu, Dan Yang, Sherry Fu, Yingjie Bian, Zhichen Sun, Junming He, Lishan Su, Liguo Zhang, Hua Peng, Yang-Xin Fu
Clearing Persistent Extracellular Antigen of Hepatitis B Virus: An Immunomodulatory Strategy To Reverse Tolerance for an Effective Therapeutic Vaccination. Journal of immunology (Baltimore, Md. : 1950) 196 (7) (2016)

Lishan Su.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Lishan Su